Your browser doesn't support javascript.
loading
Personality dimensions of patients can change during the course of parkinson's disease.
Boussac, Mathilde; Arbus, Christophe; Dupouy, Julia; Harroch, Estelle; Rousseau, Vanessa; Croiset, Aurélie; Ory-Magne, Fabienne; Rascol, Olivier; Moreau, Caroline; Rolland, Anne-Sophie; Maltête, David; Rouaud, Tiphaine; Meyer, Mylène; Drapier, Sophie; Giordana, Bruno; Anheim, Mathieu; Hainque, Elodie; Jarraya, Béchir; Benatru, Isabelle; Auzou, Nicolas; Belamri, Lhaouas; Tir, Mélissa; Marques, Ana-Raquel; Thobois, Stephane; Eusebio, Alexandre; Corvol, Jean Christophe; Devos, David; Brefel-Courbon, Christine.
Afiliação
  • Boussac M; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
  • Arbus C; Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.
  • Dupouy J; Department of Neurology, Hospital of Avignon, Avignon, France.
  • Harroch E; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
  • Rousseau V; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
  • Croiset A; CERPPS-Study and Research Center in Psychopathology and Health Psychology, University of Toulouse II Jean-Jaurès, Toulouse, France.
  • Ory-Magne F; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
  • Rascol O; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
  • Moreau C; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
  • Rolland AS; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
  • Maltête D; Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.
  • Rouaud T; Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.
  • Meyer M; Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
  • Drapier S; Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM U1239, NS-PARK/FCRIN Network, Mont-Saint-Aignan, France.
  • Giordana B; Clinique Neurologique, Hôpital Guillaume et René Laennec, NS-PARK/FCRIN Network, Boulevard Jacques Monod, Nantes, France.
  • Anheim M; Neurology Department, Nancy University Hospital, Nancy, France.
  • Hainque E; Behavior and Basal Ganglia Research Unit (EA 4712), University of Rennes 1, Rennes, France.
  • Jarraya B; Department of Neurology, Rennes University Hospital, NS-PARK/FCRIN Network, Rennes, France.
  • Benatru I; Service Universitaire de Psychiatrie, Hôpital Pasteur 1, CHU de Nice, Nice, France.
  • Auzou N; Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Belamri L; Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.
  • Tir M; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, NS-PARK/FCRIN Network, Strasbourg, France.
  • Marques AR; Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, NS-PARK/FCRIN Network, Paris, France.
  • Thobois S; Pôle Neurosciences, Foch Hospital, Suresnes, France.
  • Eusebio A; Université de Versailles Paris-Saclay, INSERM U992, CEA Neurospin, France.
  • Corvol JC; Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, NS-PARK/FCRIN Network, Poitiers, France.
  • Devos D; CHU de Bordeaux, Centre Expert Parkinson, Institut des maladies neuro-dégénératives, Bordeaux, France.
  • Brefel-Courbon C; Hôpital Fondation A de Rothschild, Service de recherche clinique, Paris, France.
PLoS One ; 16(1): e0245142, 2021.
Article em En | MEDLINE | ID: mdl-33411732
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Transtornos da Personalidade / Caráter Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Transtornos da Personalidade / Caráter Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França